Full Text | PDF

J Cancer 2021; 12(5):1538-1547. doi:10.7150/jca.52320 This issue Cite

Research Paper

Plasma exosome-derived B-cell translation gene 1: a predictive marker for the prognosis in patients with non-small cell lung cancer

Lin Wan^1#, Xiaochun Chen^2#, Jun Deng^3#, Shiliang Zhang⁴, Fan Tu⁴, Hao Pei⁴, Renjing Hu^1✉, Jun Liu^4✉, Hao Yu^3✉

1. Department of Laboratory Medicine, Wuxi Second People's Hospital, Wuxi214000, China
2. Department of Laboratory Medicine, Taizhou Second People's Hospital, Taizhou 225300, China
3. Department of Interventional Oncology, Wuxi Fifth People's Hospital, Wuxi214005, China
4. Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Wuxi214005, China
^#These authors contributed equally to this work.

✉ Corresponding authors: Renjing Hu, Department of Laboratory Medicine, Wuxi Second People's Hospital, 68 Zhongshan road, Wuxi214000, China; E-mail address: 1101058edu.cn; Jun Liu, Department of Laboratory Medicine, the Fifth People's Hospital of Wuxi Affiliated to Jiangnan University,1215 Guangrui Road, Wuxi, Jiangsu 214005, P.R. China, E-mail: 15949255828com; Hao Yu, Department of Interventional Oncology, the Fifth People's Hospital of Wuxi Affiliated to Jiangnan University,1215 Guangrui Road, Wuxi, Jiangsu 214005, P.R. China, E-mail: yuhao731117com More

Abstract

Objective: In this study, we wanted to investigate the plasma exosome-derived B-cell translocation gene 1 (BTG-1) level as a predictive marker for the prognosis in patients with Non-small cell lung cancer (NSCLC).

Patients and Methods: The expression of BTG-1 protein and BTG-1 mRNA in NSCLC tissues and adjacent tissues of 98 enrolled patients were detected by immunohistochemistry (IHC), and RT-PCR. Exosome-rich fractions were isolated from the plasma of 262 NSCLC patients. ELISA was used to detect plasma exosome-derived BTG-1 levels to evaluate the predictive value for the prognosis in patients with NSCLC.

Results: IHC staining showed that the positive expression rate of BTG-1 protein in NSCLC tissues was 58.16%, whereas that in adjacent tissues was 91.84%. RT-PCR showed that BTG-1 mRNA expression was significantly lower in NSCLC tissues than in adjacent tissues (52.04% vs 87.76%, P < 0.05). Moreover, low plasma exosome-derived BTG-1 levels were related to tumor diameter, stage, metastasis, the degree of tumor differentiation, and abnormal carcinoembryonic antigen (CEA) levels. Multivariate Cox regression analysis showed that both the disease-free survival (DFS) and overall survival (OS) were shorter in patients with low plasma exosome-derived BTG-1 level compared with patients with high plasma exosome-derived BTG-1 level.

The AUROC of plasma exosome-derived BTG-1 for 3-year DFS and 3-year OS were 0.94(95% CI; 0.91-0.98) and 0.94(95% CI: 0.90-0.98), respectively. For 3-year DFS, plasma exosome-derived BTG-1 had a sensitivity 91.0% and a specificity 82.3% for 3-year DFS, and a sensitivity 81.7% and a specificity 93.0% for 3-year OS, respectively.

Conclusions: Plasma exosome-derived BTG-1 may be a potential biomarker for the prognosis in patients with NSCLC.

Keywords: B-cell translocation gene 1, non-small cell lung cancer, exosomal, prognosis, biomarker

Citation styles

©2024 Ivyspring International Publisher. Terms of use